Vistagen's Fasedienol misses primary Phase 3 endpoints for social anxiety.

Vistagen Therapeutics notified investors that its intranasal social anxiety drug failed to meet primary and secondary endpoints in the PALISADE-4 trial. Despite a post-hoc sign of efficacy in severely ill patients, the company is pivoting to a new FDA discussion regarding a potential registrational pathway.